Search Results
Extending the Benefits of Targeting HER2 in Breast Cancer | Dana-Farber Cancer Institute
Targeting Advanced Triple-Negative Breast Cancer | Dana-Farber Cancer Institute
Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast Cancer
Research Update for HER2-Positive MBC | 2021-2022 EMBRACE MBC Virtual Forum Series
Remaining questions surrounding HER2-low breast cancer – how low can you go?
ADCs for the treatment of HER2-low breast cancer
Research Update for HER2-Positive MBC | 2023-2024 EMBRACE MBC Virtual Forum Series
Study comparing margetuximab combinations to trastuzumab combinations in HER2-positive breast cancer
Latest news in HER2-low breast cancer
Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast Cancer
Extended Adjuvant Therapy for HER2-Positive Breast Cancer
ESMO22: Breast cancer research by Sara Tolaney, MD | Dana-Farber Cancer Institute
